Table 1.
Clinical, laboratory and procedural characteristics of the overall study population, and of patients without and with the primary endpoint.
| Characteristics | overall (n = 83) | no primary endpoint (n = 77) | primary endpoint (n = 6) | p |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 65 (58–74) | 64 (58–72) | 73 (66–81) | 0.2 |
| Male sex, n (%) | 51 (61.4) | 48 (62.3) | 3 (50) | 0.7 |
| Body mass index, kg/m2 | 26.8 (25.7–29) | 26.7 (24.5–28.7) | 27.1 (26.4–29) | 0.6 |
| Medical history | ||||
| Hypertension | 78 (94) | 72 (93.5) | 6 (100) | 1 |
| Hypercholesterolemia | 77 (92.8) | 71 (92.2) | 6 (100) | 1 |
| Diabetes mellitus | 29 (34.9) | 28 (36.4) | 1 (16.7) | 0.7 |
| Active smoking | 35 (42.2) | 34 (44.2) | 1 (16.7) | 0.4 |
| Previous myocardial infarction | 15 (18.1) | 14 (18.2) | 1 (16.7) | 1 |
| CAD | 28 (33.7) | 26 (33.8) | 2 (33.3) | 1 |
| CVD | 23 (27.7) | 21 (27.3) | 2 (33.3) | 0.7 |
| PAD, CAD + CVD | 10 (12) | 9 (11.7) | 1 (16.7) | 0.6 |
| PAD + CAD | 18 (21.7) | 17 (22.1) | 1 (16.7) | 1 |
| PAD + CVD | 13 (15.7) | 12 (15.6) | 1 (16.7) | 1 |
| Laboratory data | ||||
| Haemoglobin, g/dL | 13.7 (12.5–14.7) | 13.7 (12.6–14.7) | 12.3 (11–14.6) | 0.3 |
| Haematocrit, % | 40.2 (37–42.9) | 40.4 (37.2–43.2) | 35.9 (33.8–42.9) | 0.2 |
| White blood cell count, G/L | 8.7 (6.8–10.5) | 9 (6.8–10.5) | 7.5 (6.7–8.4) | 0.2 |
| Platelet count, G/L | 210 (181–237) | 210 (181–230) | 231 (207–249) | 0.5 |
| HBDH, U/L | 106 (95–123) | 105 (95–120) | 126 (116–137) | 0.04 |
| Lactate dehydrogenase, U/L | 167 (145–190) | 167 (145–187) | 179 (166–229) | 0.2 |
| Free haemoglobin, mg/dL | 2.1 (1.4–3.3) | 2.1 (1.4–3.4) | 1.7 (1.3–2) | 0.2 |
| Serum creatinine, mg/dL | 1 (0.9–1.2) | 1 (0.9–1.1) | 1.2 (1–1.4) | 0.2 |
| C-reactive protein, mg/dL | 1.1 (0.4–1.8) | 1.1 (0.4–1.8) | 1.3 (0.4–4.3) | 0.4 |
| Procedure | ||||
| Stent implantation | 83 (100) | 77 (100) | 6 (100) | 1 |
| Number of stents/patient | 2 (1–2) | 2 (1–2) | 2 (1–2) | 0.8 |
| Medication pre-intervention | ||||
| Clopidogrel | 83 (100) | 77 (100) | 6 (100) | 1 |
| Aspirin | 83 (100) | 77 (100) | 6 (100) | 1 |
| Statins | 74 (89.2) | 68 (88.3) | 6 (100) | 1 |
| ACE inhibitors/ARB | 72 (86.7) | 66 (85.7) | 6 (100) | 1 |
| Beta blockers | 51 (61.4) | 47 (61) | 4 (66.7) | 1 |
| Calcium channel blockers | 34 (41) | 31 (40.3) | 3 (50) | 0.7 |
| Proton pump inhibitors | 39 (47) | 37 (48.1) | 2 (33.3) | 0.7 |
Continuous data are shown as median (interquartile range). Dichotomous data are shown as n (%).
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CVD, cerebrovascular disease; HBDH, α-hydroxybutyrate dehydrogenase; PAD, peripheral artery disease.